JMS Co., Ltd. (7702) AI Stock Analysis

• Market Cap: ¥10.31B
• Dividend Yield: 4.03%
• Average Volume (3M): 32.27K
• Price to Earnings (P/E): 116.2
• Beta (1Y): 0.68
• Revenue Growth: 6.83%
• EPS Growth: N/A
• Country: JP
• Employees: 5,283
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -4.90
• Shares Outstanding: 24,733,465
• 10 Day Avg. Volume: 18,820
• 30 Day Avg. Volume: 32,270
• PEG Ratio: 0.23
• Price to Book (P/B): 0.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 53 Neutral
• Price Target: ¥429.00 ▲(1.66%Upside)

The stock is rated moderately due to a strong financial position but faces profitability challenges and technical weaknesses. High P/E ratio indicates overvaluation, though a decent dividend yield partially offsets this.

JMS Co., Ltd. Business Overview & Revenue Model

Company Description

JMS Co., Ltd. (7702) is a Japan-based company primarily engaged in the manufacturing and sale of medical devices and related products. The company operates in the healthcare sector, focusing on developing innovative solutions for medical professionals and facilities. JMS Co., Ltd. offers a range of products, including infusion and transfusion systems, dialysis systems, and other medical equipment designed to enhance patient care and improve medical outcomes.

How the Company Makes Money

JMS Co., Ltd. generates revenue primarily through the sale of its medical devices and equipment to hospitals, clinics, and other healthcare facilities. The company's key revenue streams include the infusion and transfusion systems, which are essential for administering fluids and medications, and dialysis systems, which are crucial for patients with kidney failure. Additionally, JMS Co., Ltd. may engage in partnerships with medical institutions and research organizations to develop advanced healthcare solutions, thereby driving further sales and enhancing its market presence. The company also benefits from maintaining a strong distribution network to ensure the broad availability of its products in various regions.

JMS Co., Ltd. Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
69.89B	65.29B	63.74B	58.17B	57.58B	58.57B
	Gross Profit
15.46B	14.09B	14.60B	14.27B	15.10B	15.64B
	EBIT
474.00M	-268.00M	724.00M	980.00M	2.13B	2.31B
	EBITDA
4.26B	4.08B	4.32B	4.34B	5.37B	5.47B
	Net Income Common Stockholders
119.00M	-36.00M	281.00M	826.00M	1.74B	1.98B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
8.88B	10.31B	6.33B	6.81B	6.22B	6.02B
	Total Assets
86.27B	84.71B	74.41B	71.97B	69.08B	66.57B
	Total Debt
26.07B	26.92B	19.75B	18.71B	18.50B	18.45B
	Net Debt
17.18B	16.62B	13.42B	12.11B	12.53B	12.69B
	Total Liabilities
44.86B	43.96B	35.71B	34.88B	34.09B	34.10B
	Stockholders Equity
41.27B	40.57B	38.53B	36.96B	34.84B	32.34B
Cash Flow		Free Cash Flow
0.00	498.00M	-1.07B	1.14B	481.00M	263.00M
	Operating Cash Flow
0.00	3.14B	2.48B	4.40B	3.74B	3.56B
	Investing Cash Flow
0.00	-4.24B	-3.69B	-3.68B	-3.25B	-3.34B
	Financing Cash Flow
0.00	4.78B	525.00M	-499.00M	-535.00M	-1.19B

JMS Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 422.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7702, the sentiment is Negative. The current price of 422 is below the 20-day moving average (MA) of 426.90, below the 50-day MA of 439.98, and below the 200-day MA of 453.29, indicating a bearish trend. The MACD of -5.54 indicates Negative momentum. The RSI at 39.32 is Neutral, neither overbought nor oversold. The STOCH value of 9.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7702.

JMS Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7980	78 Outperform	¥5.67B	7.26		1.88%	8.60%	33.64%
7730	76 Outperform	¥118.12B	19.57		3.25%	11.54%	-8.30%
7743	64 Neutral	¥13.35B	12.22		3.40%	2.58%	-53.08%
3593	63 Neutral	$55.17B	57.54	1.87%	1.94%	0.10%	-41.21%
7979	61 Neutral	¥72.83B	16.80		2.40%	15.55%	42.14%
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%
7702	53 Neutral	¥10.31B	116.15		4.03%	6.83%	―

JMS Co., Ltd. Corporate Events

JMS Co., Ltd. Reports Improved Financial Performance Amidst Cash Flow Challenges

JMS Co., Ltd. reported a 6.8% increase in net sales for the fiscal year ending March 2025, reaching 69,749 million yen. The company’s operating profit turned positive at 872 million yen, compared to a loss in the previous year, indicating improved financial performance. Despite a decrease in comprehensive income by 76%, the company showed a significant increase in ordinary profit by 252.7%. The capital adequacy ratio improved to 50.1%, reflecting a stable financial position. However, cash flows from operating activities decreased significantly, and cash and equivalents at the end of the period dropped to 5,507 million yen.